Page last updated: 2024-11-05

tolbutamide and Prader-Willi Syndrome

tolbutamide has been researched along with Prader-Willi Syndrome in 1 studies

Tolbutamide: A sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290)
tolbutamide : An N-sulfonylurea that consists of 1-butylurea having a tosyl group attached at the 3-position.

Prader-Willi Syndrome: An autosomal dominant disorder caused by deletion of the proximal long arm of the paternal chromosome 15 (15q11-q13) or by inheritance of both of the pair of chromosomes 15 from the mother (UNIPARENTAL DISOMY) which are imprinted (GENETIC IMPRINTING) and hence silenced. Clinical manifestations include MENTAL RETARDATION; MUSCULAR HYPOTONIA; HYPERPHAGIA; OBESITY; short stature; HYPOGONADISM; STRABISMUS; and HYPERSOMNOLENCE. (Menkes, Textbook of Child Neurology, 5th ed, p229)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
ROYER, P1

Other Studies

1 other study available for tolbutamide and Prader-Willi Syndrome

ArticleYear
[DIABETES MELLITUS IN THE WILLI-PRADER SYNDROME].
    Journees annuelles de diabetologie de l'Hotel-Dieu, 1963

    Topics: Adolescent; Child; Congenital Abnormalities; Diabetes Mellitus; Diabetes Mellitus, Type 1; Dwarfism;

1963